US FDA oncology drug approvals in 2014

被引：5

作者：

Wolford, Juliet E. ^{[1
]}

Tewari, Krishnansu S. ^{[1
]}

机构：

[1] Univ Calif Irvine, Med Ctr, Chao Family NCI Designated Comprehens Canc Ctr, Orange, CA 92868 USA

来源：

FUTURE ONCOLOGY | 2015年 / 11卷 / 13期

关键词：

accelerated approval; cancer drugs; orphan drug designation; priority review; US FDA; regulatory approval; OLAPARIB MAINTENANCE THERAPY; OVARIAN-CANCER; DOUBLE-BLIND; MULTICENTER; BEVACIZUMAB; IPILIMUMAB; NIVOLUMAB; IBRUTINIB; MELANOMA;

D O I：

10.2217/FON.15.106

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cancer is a close second to heart disease for cause of death in the USA, and could soon surpass heart disease as the population ages and the incidence of cancer continues to increase. While heart disease can be addressed through behavior modification and education (e. g., smoking cessation, dietary changes, exercises that promote cardiovascular fitness), pharmacology and improved surgical devices and methods, cancer ultimately requires improved and novel drug treatments to bring mortality rates down. In 2014, the US FDA approved 17 drugs and/or drug combinations in 12 disease sites for a total of 19 indications in melanoma, hematologic malignancies, gastrointestinal carcinoma, non-small-cell lung cancer, gynecologic malignancies and lymphoma/lymphoproliferative disorders.

引用

页码：1931 / 1945

页数：15

共 35 条

[31] Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial [J].

van Rhee, Frits ;

Wong, Raymond S. ;

Munshi, Nikhil ;

Rossi, Jean-Francois ;

Ke, Xiao-Yan ;

Fossa, Alexander ;

Simpson, David ;

Capra, Marcelo ;

Liu, Ting ;

Hsieh, Ruey Kuen ;

Goh, Yeow Tee ;

Zhu, Jun ;

Cho, Seok-Goo ;

Ren, Hanyun ;

Cavet, James ;

Bandekar, Rajesh ;

Rothman, Margaret ;

Puchalski, Thomas A. ;

Reddy, Manjula ;

van de Velde, Helgi ;

Vermeulen, Jessica ;

Casper, Corey .

LANCET ONCOLOGY, 2014, 15 (09) :966-974

[32] Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera [J].

Vannucchi, Alessandro M. ;

Kiladjian, Jean Jacques ;

Griesshammer, Martin ;

Masszi, Tamas ;

Durrant, Simon ;

Passamonti, Francesco ;

Harrison, Claire N. ;

Pane, Fabrizio ;

Zachee, Pierre ;

Mesa, Ruben ;

He, Shui ;

Jones, Mark M. ;

Garrett, William ;

Li, Jingjin ;

Pirron, Ulrich ;

Habr, Dany ;

Verstovsek, Srdan .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (05) :426-435

[33] Do molecularly targeted agents in oncology have reduced attrition rates? [J].

Walker, Ian ;

Newell, Herbie .

NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (01) :15-16

[34] Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial [J].

Wilke, Hansjochen ;

Muro, Kei ;

Van Cutsem, Eric ;

Oh, Sang-Cheul ;

Bodoky, Gyoergy ;

Shimada, Yasuhiro ;

Hironaka, Shuichi ;

Sugimoto, Naotoshi ;

Lipatov, Oleg ;

Kim, Tae-You ;

Cunningham, David ;

Rougier, Philippe ;

Komatsu, Yoshito ;

Ajani, Jaffer ;

Emig, Michael ;

Carlesi, Roberto ;

Ferry, David ;

Chandrawansa, Kumari ;

Schwartz, Jonathan D. ;

Ohtsu, Atsushi .

LANCET ONCOLOGY, 2014, 15 (11) :1224-1235

[35] Nivolumab plus Ipilimumab in Advanced Melanoma [J].

Wolchok, Jedd D. ;

Kluger, Harriet ;

Callahan, Margaret K. ;

Postow, Michael A. ;

Rizvi, Naiyer A. ;

Lesokhin, Alexander M. ;

Segal, Neil H. ;

Ariyan, Charlotte E. ;

Gordon, Ruth-Ann ;

Reed, Kathleen ;

Burke, Matthew M. ;

Caldwell, Anne ;

Kronenberg, Stephanie A. ;

Agunwamba, Blessing U. ;

Zhang, Xiaoling ;

Lowy, Israel ;

Inzunza, Hector David ;

Feely, William ;

Horak, Christine E. ;

Hong, Quan ;

Korman, Alan J. ;

Wigginton, Jon M. ;

Gupta, Ashok ;

Sznol, Mario .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (02) :122-133

← 1 2 3 4 →